Get the Stockscreener App
0.6021
1.81%
0.0107
After Hours:
.61
0.0079
+1.31%
Scinai Immunotherapeutics Ltd Adr stock is traded at $0.6021, with a volume of 10,267.
It is up +1.81% in the last 24 hours and down -15.24% over the past month.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.
See More
Previous Close:
$0.5914
Open:
$0.5701
24h Volume:
10,267
Relative Volume:
0.20
Market Cap:
$2.13M
Revenue:
$1.26M
Net Income/Loss:
$-8.55M
P/E Ratio:
-0.0491
EPS:
-12.2724
Net Cash Flow:
$-6.38M
1W Performance:
+3.81%
1M Performance:
-15.24%
6M Performance:
-56.37%
1Y Performance:
-68.64%
1-Day Range:
$0.5701
$0.61
1-Week Range:
$0.568
$0.6175
52-Week Range:
$0.55
$6.18
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Company Profile
Name
Scinai Immunotherapeutics Ltd Adr
Sector
Industry
Phone
972-8-9302529
Address
JERUSALEM BIOPARK, 2ND FLOOR, JERUSALEM
Compare SCNI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCNI
Scinai Immunotherapeutics Ltd Adr
|
0.6021 | 2.09M | 1.26M | -8.55M | -6.38M | -12.27 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Latest News
Scinai Completes Corporate Reorganization Separating CDMO and R&D Operations - Contract Pharma
Cash per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – FWB:2F5 - TradingView
Total debt per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – FWB:2F5 - TradingView
Scinai completes corporate reorganization, separates CDMO unit - Investing.com
Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities - Barchart
Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration - Sahm
Scinai Immunotherapeutics (NASDAQ: SCNI) details going concern, CDMO and NanoAb risks - Stock Titan
Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring 2026 - Finviz
Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price - Finviz
Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price - Benzinga
Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised 12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept - Finviz
Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept - Barchart.com
SUNation Energy Inc. (NASDAQ:SUNE) Short Interest Update - Defense World
Enerflex (NYSE:EFXT) Shares Gap Up Following Dividend Announcement - Defense World
Scinai receives expanded grant for robotic manufacturing system - Investing.com
Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform - Finviz
Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm - Barchart
Scinai Immunotherapeutics (NASDAQ:SCNI) Shares Down 3.1% – Here’s Why - Defense World
Scinai Immunotherapeutics Reports Growth and Pipeline Progress - MSN
Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL - Finviz
Working capital per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView — Track All Markets
Coca-Cola HBC (OTCMKTS:CCHGY) Trading 3.7% Higher – Should You Buy? - Defense World
PCCW (OTCMKTS:PCWLF) Trading Down 7.9% – Here’s Why - Defense World
Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Sees Large Drop in Short Interest - Defense World
Scinai Immunotherapeutics (NASDAQ:SCNI) Stock Price Down 1.3% – Should You Sell? - Defense World
Revenue per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – BER:2F5 - TradingView — Track All Markets
Scinai Immunotherapeutics (NASDAQ:SCNI) Shares Up 3% – What’s Next? - Defense World
Scinai reports revenue growth as CDMO business expands By Investing.com - Investing.com India
Scinai reports revenue growth as CDMO business expands - Investing.com
Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances - Barchart.com
Revenue per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView
SCNI | Scinai Immunotherapeutics Ltd. ADR SEC Filings - MarketWatch
Scinai Immunotherapeutics schedules annual meeting for December 22 - Investing.com
Scinai Immunotherapeutics schedules annual meeting for December 22 By Investing.com - Investing.com South Africa
Cash per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – BER:2F5 - TradingView
Scinai receives $246,000 grant to expand biotech manufacturing - Investing.com
Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet - Finviz
Scinai’s PC111 antibody shows promise for pemphigus treatment - Investing.com
Scinai Immunotherapeutics (SCNI) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat
Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology" - Finviz
Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l. - Finviz
Scinai Immunotherapeutics Faces Financial Challenges, Seeks Growth - TipRanks
Scinai Announces Annual Financial Results for 2024 - Finviz
Scinai Immunotherapeutics (NASDAQ: SCNI) Enters Option Agreement to Acquire Italian Biotech Pincell - The Globe and Mail
CERo Therapeutics (CERO) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
Scinai Immunotherapeutics (SCNI) Stock Forecast and Price Target 2025 - MarketBeat
Scinai Immunotherapeutics enacts reverse split to meet Nasdaq rules By Investing.com - Investing.com India
Ayana Pharma Signs Master Service Agreement with Scinai Immunotherapeutics - Contract Pharma
symbol__ Stock Quote Price and Forecast - CNN
Scinai Immunotherapeutics (SCNI) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
Scinai Immunotherapeutics Ltd. Sponsored ADR Cash Flow – NASDAQ:SCNI - TradingView
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):